dhr stock Danaher Corporation Guide

Danaher Corporation (DHR) — Stock

Overview: dhr stock is the ticker symbol for Danaher Corporation’s common stock, listed on the New York Stock Exchange (NYSE). Danaher is a diversified global science and technology company focused on life sciences, diagnostics, and environmental & applied solutions. The equity represents ownership in Danaher and is followed by institutional and retail investors worldwide.

Infobox (stock summary)

• Ticker: DHR
• Exchange: NYSE (primary listing)
• ISIN: (see company filings / market data; varies by share class)
• Current price: varies; see market data (as of 2026-01-24 Benzinga reported $233.84)
• Market capitalization: varies; as of 2026-01-24 Benzinga reported $165.19 billion
• Shares outstanding / float: see most recent 10-Q / 10-K for exact figures
• Primary indices: S&P 500, healthcare/science sector indexes (constituent membership subject to index provider)
• Sector / Industry: Healthcare / Life Sciences, Diagnostics, Scientific Instruments

Company overview (context for the stock)

Danaher Corporation is a diversified science and technology company whose operations span three major segments: Life Sciences (research instruments, reagents), Diagnostics (laboratory and clinical diagnostics), and Environmental & Applied Solutions (water quality, product identification). The company was founded in the late 1960s and is headquartered in Washington, D.C., with major operations and R&D centers across the globe. Holding shares of dhr stock gives investors exposure to these end markets — principally pharmaceutical and biotech research spending, clinical diagnostics, and industrial / environmental customers.

Stock listing and trading information

Ticker and exchange

The ticker symbol for Danaher common stock is DHR and its primary listing is on the New York Stock Exchange (NYSE). Regular trading hours for DHR follow U.S. equity market hours (typically 9:30 a.m. to 4:00 p.m. Eastern Time), with pre-market and after-hours trading available on electronic venues. Market participants use real-time quote services and broker platforms to see up-to-date pricing for dhr stock.

Trading characteristics

dhr stock typically exhibits high liquidity among large-cap healthcare names. Average daily share volume and intraday liquidity can fluctuate with market conditions, corporate events, and earnings cycles; for the most recent average daily volume reference market-data providers or the company’s investor relations updates. DHR is included in major ETFs and passive funds that track the S&P 500 and healthcare-related indices, which influences its float turnover and institutional ownership patterns.

Options and derivatives

Listed options on DHR are commonly available on U.S. options exchanges. Traders and investors use options on dhr stock for hedging, income generation (covered calls), and directional strategies. Standard monthly expirations as well as weekly options (when available) provide flexibility; implied volatility and open interest can be referenced on options analytics platforms. Professional and retail participants monitor options volume as a gauge of near-term sentiment.

Historical price performance

Price history and milestones

Over multi-year horizons, dhr stock has delivered substantial total returns driven by organic growth, acquisitions, and operational improvements across its platforms. According to Benzinga data, Danaher has outperformed the broader market over the past decade on an annualized basis. Long-term milestones include multi-year uptrends tied to the company’s expansion in life sciences tools and diagnostics, as well as periodic pullbacks around macro selloffs and sector rotations.

Recent performance and 52-week range

As of 2026-01-24, Benzinga reported a closing price of $233.84 for DHR. Short- and medium-term movements in dhr stock reflect earnings results, guidance updates, acquisitions and macro factors affecting biomedical capital spending. For the latest 52-week high and low, consult real-time market-data services; these ranges provide quick context for current price relative to recent volatility.

Stock splits and corporate actions

Historical stock splits, reverse splits, and corporate reorganizations that affect DHR share count are documented in Danaher’s SEC filings and investor relations releases. Investors should check the company’s 10-K, 10-Q, and press releases for official records of any splitting events or significant corporate actions (spin-offs, large acquisitions) that materially alter outstanding shares or capital structure.

Financial metrics and valuation

Key financials

Key public financial metrics for Danaher include revenue, net income, and earnings per share (EPS), reported quarterly and annually. For the most accurate and audited figures, refer to the company’s latest Form 10-K and Form 10-Q filed with the SEC and summarized in investor presentations. Commonly quoted figures include trailing twelve months (TTM) revenue and TTM EPS which underpin valuation comparisons for dhr stock.

Valuation ratios

Analysts and investors commonly use P/E (price-to-earnings), forward P/E, EV/EBITDA, P/S (price-to-sales), and PEG ratios to value dhr stock relative to peers. Danaher’s valuation tends to reflect its growth profile, margins, and acquisition-driven expansion. Comparing these ratios against peer companies in life sciences instruments and diagnostics helps contextualize whether DHR trades at a premium or discount to sector averages.

Profitability and margins

Danaher’s reported gross margin and operating margin are key indicators of its profitability across business segments. Over time, margin trends indicate efficiency gains, pricing power on instruments and consumables, and integration benefits from acquisitions. Investors reviewing dhr stock track margin expansion or contraction in quarterly results and management commentary.

Dividends and shareholder returns

Danaher has a history of returning capital to shareholders through dividends and share repurchases. Dividend yield for dhr stock varies with the market price and declared payout; payout ratio and dividend growth history are documented in company disclosures. Buyback programs and repurchase activity can complement dividend policy as part of overall shareholder return. For up-to-date yield figures and program sizes, refer to the latest investor relations materials and SEC filings.

Ownership and major holders

Institutional investors typically hold a significant portion of dhr stock, including mutual funds, pension funds, and ETFs that include DHR in their portfolios. Major holders and institutional ownership percentages are available in the company’s proxy statements and on market-data platforms. Insider ownership is generally a small percentage compared with institutional holdings; notable insider transactions are reported via SEC Form 4 filings and summarized by market-data services.

Analyst coverage and market sentiment

Ratings and price targets

Sell-side analysts covering dhr stock publish ratings and price targets which aggregate into a consensus view (Buy / Hold / Sell mix). Price targets and rating changes typically follow earnings, guidance updates, and material corporate developments. Investors use consensus metrics as one input among many when researching DHR; for specific analyst figures consult market-data summaries and analyst reports.

Sell-side themes and catalysts

Recurring analyst themes for dhr stock include demand trends for life-science capital equipment and consumables, cyclical patterns in diagnostics testing volumes, margin expansion from product mix and acquisitions, and the timing/impact of large inorganic transactions. Legal, regulatory, or reimbursement issues that affect diagnostics customers also appear as catalyst considerations in coverage notes.

Corporate governance and management

Key executives of Danaher — including the CEO and CFO — shape strategic direction that impacts dhr stock. The board of directors, governance practices, and executive compensation are disclosed in proxy statements. Investors review governance items for potential effects on capital allocation, M&A discipline, and long-term strategy execution.

Key business drivers and investment thesis

Primary growth drivers for Danaher include continued investment in life-science research tools, recurring revenue from consumables and service contracts, expansion of diagnostics platforms into new markets, and disciplined acquisitions that add high-margin capabilities. Those examining dhr stock will often highlight Danaher’s operating model, portfolio diversification across resilient end markets, and history of converting innovation into recurring revenue streams.

Risks and controversies

Risks relevant to holders of dhr stock include cyclicality in capital spending by pharmaceutical and biotech customers, regulatory or reimbursement changes affecting diagnostics, competitive pressures from large diversified players and niche specialists, and integration risks from acquisitions. Any material legal actions, class actions, or regulatory investigations are disclosed in SEC filings and major news reports and can influence near-term sentiment.

Financial reporting and earnings

Earnings cadence

Danaher typically reports quarterly results and updates full-year guidance when appropriate. Earnings releases, conference calls, and investor presentations offer insights into performance versus expectations and management’s view on demand trends. Market reactions to quarterly results can produce significant intraday moves in dhr stock.

Historical earnings and notable quarters

Notable quarters for dhr stock often involve results that materially beat or miss consensus, major acquisitions announced or closed, or guidance changes. Historical beats have reinforced investor confidence in the company’s operating model; conversely, unexpected softness in end markets can lead to noticeable price reactions. For specific quarter-by-quarter details consult earnings press releases and transcripts.

Market positioning and peers

Danaher competes with diversified scientific and medical companies across segments. Comparable companies vary by sub-industry (e.g., life-science tools, diagnostics, environmental instruments). Analysts benchmark dhr stock against peers on revenue growth, margins, and valuation multiples to assess relative performance. Familiarity with competitive product lines and customer overlaps helps contextualize Danaher’s market position.

Technical analysis and investor tools

Traders often apply technical analysis to dhr stock using tools such as moving averages (50-day, 200-day), trendlines, RSI, MACD, and volume-based indicators. Charting platforms and brokerage resources provide intraday quotes and technical overlays. Long-term investors may combine technical cues with fundamental analysis to time entries or monitor trends.

Regulatory and macro considerations

Macro factors that influence dhr stock include global healthcare spending, pharmaceutical and biotech capital expenditure cycles, currency fluctuations (for multinational revenue), and regulatory developments affecting diagnostics and laboratory operations. Trade policies or tariffs on instrument components can have operational implications, while broad market conditions and interest rates affect valuation multiples.

See also

• Danaher Corporation (company profile)
• Life sciences industry overview
• Common valuation metrics for healthcare stocks
• List of major U.S. stock exchanges and trading hours

References

Sources include Danaher Investor Relations, SEC filings (Form 10-K and 10-Q), and market-data pages summarized by providers such as Benzinga, Yahoo Finance, MarketWatch, TradingView, MacroTrends and Nasdaq. Specific figures cited in this article reference a Benzinga market-data summary published and accessed as of 2026-01-24.

As of 2026-01-24, according to Benzinga, Danaher had a market capitalization of $165.19 billion and a reported price of $233.84 for DHR. Benzinga noted that over the past 10 years Danaher outperformed the broader market by 1.41% annualized, producing an average annual return of 15.21%. Benzinga’s example: buying $1,000 of DHR 10 years ago would be worth approximately $4,131.81 based on historical price movement cited by Benzinga.

External links

For real-time quotes and filings, consult Danaher’s investor relations materials and publicly filed SEC documents, and market-data platforms. For trading DHR, consider regulated platforms and ensure your broker provides timely market access; Bitget offers equity trading services and research tools for investors seeking exposure to publicly listed securities.

Notes on sourcing and updates

Price and market-data fields are time-sensitive. For updated figures on dhr stock (current price, market cap, 52-week range, shares outstanding), reference real-time market feeds and the company’s most recent SEC filings. Historical context and multi-year performance can be cross-checked with long-term data providers such as MacroTrends and verified company annual reports.

Additional factual snapshot (timely data as of 2026-01-24)

• Reported DHR price (Benzinga): $233.84 (as of 2026-01-24)
• Reported market capitalization (Benzinga): $165.19 billion (as of 2026-01-24)
• 10-year average annual return (Benzinga): 15.21% (DHR outperformed market by 1.41% annually over that period)
• Example long-term growth (Benzinga): $1,000 invested in DHR 10 years prior would be ~ $4,131.81 as of the price snapshot

All figures above are subject to revision as market prices change and should be verified against primary sources for investment decisions. The data cited are reported by Benzinga on 2026-01-24 and summarized here for context about dhr stock.

How to follow dhr stock and next steps

If you want to monitor dhr stock in real time, use reputable market-data platforms, subscribe to the company’s investor alerts, and review SEC filings for definitive financial statements. For trading access, consider regulated brokers that provide U.S.-listed equity execution and research tools; Bitget provides trading infrastructure and investor resources for users looking to trade publicly listed securities including DHR.

Further exploration: request a deeper dive into any of the sections above — for example, a full financial ratio comparison to peers, historical total-return charts over specific horizons, or a detailed summary of Danaher’s major acquisitions and how they influenced dhr stock performance.

This article is informational and factual in nature. It does not constitute investment advice, recommendation, or endorsement. All data points should be verified with original sources such as Danaher’s SEC filings and real-time market-data services.